Meeting
2020 ASCO Virtual Scientific Program
TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
Authors
Gayathri Anandappa
The Royal Marsden NHS Foundation Trust, London, United Kingdom
Gayathri Anandappa , Naureen Starling , Clare Peckitt , Annette Bryant , Ruwaida Begum , Paul Carter , Shelby Hatt , Shelize Sadrudin Khakoo , Andrea Turner , Shannon Kidd , Julie Duncan , Laura Hobbis , Kyriaki Giorgakoudi , Michaela Smalley , David Lowery , Pete Wheatstone , Ian Chau , Michael Hubank , David Cunningham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT04050345
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4120)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4120
Abstract #
TPS4120
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.
First Author: Shusuke Yagi
Poster
2017 ASCO Annual Meeting
Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.
First Author: In Gyu Hwang
Poster
2022 ASCO Annual Meeting
Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
First Author: Yoanna S Pumpalova
Poster
2021 ASCO Annual Meeting
JCOG1805 (PanDRa-BD study): A randomized controlled study of adjuvant chemotherapy for stage II colorectal cancer patients at high-risk of developing recurrence according to T-stage and three selected pathological factors (Pn, DR, and BD).
First Author: Megumi Ishiguro